507 related articles for article (PubMed ID: 24282027)
1. Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
Stafa K; Tsika E; Moser R; Musso A; Glauser L; Jones A; Biskup S; Xiong Y; Bandopadhyay R; Dawson VL; Dawson TM; Moore DJ
Hum Mol Genet; 2014 Apr; 23(8):2055-77. PubMed ID: 24282027
[TBL] [Abstract][Full Text] [Related]
2. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
[TBL] [Abstract][Full Text] [Related]
3. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.
Su YC; Qi X
Hum Mol Genet; 2013 Nov; 22(22):4545-61. PubMed ID: 23813973
[TBL] [Abstract][Full Text] [Related]
5. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
6. 14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening.
Lavalley NJ; Slone SR; Ding H; West AB; Yacoubian TA
Hum Mol Genet; 2016 Jan; 25(1):109-22. PubMed ID: 26546614
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein.
Niu J; Yu M; Wang C; Xu Z
J Neurochem; 2012 Aug; 122(3):650-8. PubMed ID: 22639965
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.
Trancikova A; Mamais A; Webber PJ; Stafa K; Tsika E; Glauser L; West AB; Bandopadhyay R; Moore DJ
PLoS One; 2012; 7(10):e47784. PubMed ID: 23082216
[TBL] [Abstract][Full Text] [Related]
9. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
[TBL] [Abstract][Full Text] [Related]
10. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
[TBL] [Abstract][Full Text] [Related]
11. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
Tsika E; Moore DJ
Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1.
Wang X; Yan MH; Fujioka H; Liu J; Wilson-Delfosse A; Chen SG; Perry G; Casadesus G; Zhu X
Hum Mol Genet; 2012 May; 21(9):1931-44. PubMed ID: 22228096
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
14. The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation.
Cogo S; Ho FY; Tosoni E; Tomkins JE; Tessari I; Iannotta L; Montine TJ; Manzoni C; Lewis PA; Bubacco L; Chartier Harlin MC; Taymans JM; Kortholt A; Nichols J; Cendron L; Civiero L; Greggio E
Brain Res; 2022 Mar; 1778():147781. PubMed ID: 35016853
[TBL] [Abstract][Full Text] [Related]
15. GTPase activity plays a key role in the pathobiology of LRRK2.
Xiong Y; Coombes CE; Kilaru A; Li X; Gitler AD; Bowers WJ; Dawson VL; Dawson TM; Moore DJ
PLoS Genet; 2010 Apr; 6(4):e1000902. PubMed ID: 20386743
[TBL] [Abstract][Full Text] [Related]
16. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
18. The neurobiology of LRRK2 and its role in the pathogenesis of Parkinson's disease.
Rideout HJ; Stefanis L
Neurochem Res; 2014; 39(3):576-92. PubMed ID: 23729298
[TBL] [Abstract][Full Text] [Related]
19. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 transport is regulated by its novel interacting partner Rab32.
Waschbüsch D; Michels H; Strassheim S; Ossendorf E; Kessler D; Gloeckner CJ; Barnekow A
PLoS One; 2014; 9(10):e111632. PubMed ID: 25360523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
